Share on StockTwits

Stemline Therapeutics (NASDAQ:STML) COO Kenneth Hoberman acquired 2,000 shares of the stock on the open market in a transaction dated Tuesday, September 2nd. The stock was purchased at an average cost of $10.99 per share, with a total value of $21,980.00. Following the completion of the transaction, the chief operating officer now directly owns 89,535 shares of the company’s stock, valued at approximately $983,990. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Stemline Therapeutics (NASDAQ:STML) traded down 0.27% during mid-day trading on Wednesday, hitting $10.92. 142,012 shares of the company’s stock traded hands. Stemline Therapeutics has a 52-week low of $10.509 and a 52-week high of $47.25. The stock’s 50-day moving average is $11.66 and its 200-day moving average is $16.40. The company’s market cap is $141.4 million.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Thursday, August 14th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.71) by $0.24. On average, analysts predict that Stemline Therapeutics will post $-2.39 earnings per share for the current fiscal year.

Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.